Show simple item record

dc.contributor.authorSleijfer, S
dc.contributor.authorRizzo, E
dc.contributor.authorLitière, S
dc.contributor.authorMathijssen, RHJ
dc.contributor.authorJudson, IR
dc.contributor.authorGelderblom, H
dc.contributor.authorVan Der Graaf, WTA
dc.contributor.authorGronchi, A
dc.date.accessioned2018-03-28T11:44:24Z
dc.date.issued2018-08
dc.identifier.citationActa oncologica (Stockholm, Sweden), 2018, 57 (8), pp. 1117 - 1126
dc.identifier.issn0284-186X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1617
dc.identifier.eissn1651-226X
dc.identifier.doi10.1080/0284186x.2018.1449248
dc.description.abstractINTRODUCTION:As both anti-tumour effects and toxicity are thought to be dose-dependent, patients with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubicin-induced hematological toxicity is associated with outcome in advanced soft tissue sarcoma (STS) patients. In addition, risk factors for hematological toxicity were explored. METHODS:Worst haematological toxicities (anaemia, leukopenia, neutropenia and thrombocytopenia) seen during treatment were scored according to CTCAE toxicity score. Differences in overall survival (OS), progression free survival (PFS) and response rate (RR) between patients with or without high haematological toxicity (grades 0-2 vs. 3-4) were assessed using conventional statistical tests. Associations between baseline characteristics and hematological toxicity were established using logistic multivariate regression. RESULTS:In 557 patients eligible for this analysis, 47.2% of the patients received at least six cycles of treatment; 45% stopped treatment early due to progression, 3% because of toxicity. Relative dose intensity (RDI) was constant over the cycles. OS, PFS, and RR did not differ between patients with grade 3/4 toxicity during treatment versus those with grade 1/2. Risk factors for grade 3/4 haematological toxicity, in particular neutropenia, were age above 60 years, low BMI, and female gender. CONCLUSION:In this large series, risk factors for haematological toxicity in STS patients receiving doxorubicin monotherapy were revealed. The finding that there was no association between outcome and haematological toxicity during doxorubicin treatment may be useful to reassure advanced STS patients that failure to experience haematological toxicity during treatment does not equate to under-treatment.
dc.formatPrint-Electronic
dc.format.extent1117 - 1126
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectSarcoma
dc.subjectBone Neoplasms
dc.subjectHematologic Diseases
dc.subjectDoxorubicin
dc.subjectAntibiotics, Antineoplastic
dc.subjectDisease-Free Survival
dc.subjectTreatment Outcome
dc.subjectRetrospective Studies
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.titlePredictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.
dc.typeJournal Article
dcterms.dateAccepted2018-02-23
rioxxterms.versionofrecord10.1080/0284186x.2018.1449248
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfActa oncologica (Stockholm, Sweden)
pubs.issue8
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.publication-statusPublished
pubs.volume57en_US
pubs.embargo.termsNo embargo
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen
dc.contributor.icrauthorJudson, Ianen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0